

# Entheon Biomedical Lists on OTCQB Venture Market

Vancouver, British Columbia--(Newsfile Corp. - May 5, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: "1XU1") ("**Entheon**" or the "**Company**"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that it has been approved for trading on the OTCQB Venture Market ("OTCQB") effective May 5, 2021.

"We are thrilled to be up-listing on to the OTCQB, which will allow for greater engagement with our U.S. investor base. As we advance our DMT addiction therapy program toward human trials, continue R&D on our diagnostic and patient-monitoring platform, and scale up commercial availability of our subsidiary, HaluGen Life Science's Psychedelics Genetic Test, we are pleased to be gaining increased visibility and investor access within the U.S. market," said Timothy Ko, CEO of Entheon.

The shares will trade on the OTCQB under trading symbol "ENTBF". The Company's shares will continue to trade on the Canadian Securities Exchange (CSE) under the symbol "ENBI" as well as the Frankfurt Stock Exchange (FSE) under the symbol "1XU1".

This U.S. listing will provide the Company with access to a broader base of U.S. and international retail and institutional investors, ultimately providing investors with increased access to data, transparency and liquidity.

Investors can find real-time quotes and market information for the Company on [www.otcm Markets.com](http://www.otcm Markets.com).

## **About Entheon Biomedical Corp.**

Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective N,N-dimethyltryptamine based psychedelic therapeutic products ("**DMT Products**") for the purposes of treating addiction and substance use disorders. Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.

## **On Behalf of the Board of Directors,**

"Timothy Ko"  
Timothy Ko, CEO

## **For more information, please contact the Company at:**

Entheon Biomedical Corp.  
Joseph Cullen, Investor Relations  
Telephone: +1 (778) 919-8615  
[Joe@entheonbiomedical.com](mailto:Joe@entheonbiomedical.com)  
<https://entheonbiomedical.com/>

## **For media inquiries, please contact Crystal Quast at:**

Bullseye Corporate  
Crystal Quast  
Telephone: +1 (647) 529-6364  
[Quast@BullseyeCorporate.com](mailto:Quast@BullseyeCorporate.com)

## **Cautionary Note on Forward Looking Information**

*This news release contains forward-looking statements and forward-looking information within the*

*meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, this news release contains forward-looking statements and information relating to the engagement and advisory services of Nancy Maher as "Special Advisor", and other matters. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.*

*Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company's ability to raise further capital and the Company's ability to obtain regulatory and exchange approvals. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.*

*Neither the CSE nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.*

**ENTHEON**

To view the source version of this press release, please visit  
<https://www.newsfilecorp.com/release/82984>